A Diffusable Factor in Scottish Coagulation Factor Concentrates Can Inhibit Lymphocyte Transformation in vitro
- 1 September 1985
- journal article
- research article
- Published by Wiley in Vox Sanguinis
- Vol. 49 (3) , 187-194
- https://doi.org/10.1111/j.1423-0410.1985.tb00792.x
Abstract
Coagulation factor VIII and IX concentrates produced in Scotland inhibited human lymphocyte transformation induced by lectins or the recall antigen, purified protein derivative of tuberculin (PPD). Although concanavalin A could bind factor VIII directly and PHA could bind factor IX directly, most of the inhibition was not due to direct clotting factor-lectin interaction nor to simple toxicity. Most of the inhibitory activity from both clotting factors could be removed by dialysis. A similar degree of inhibition was observed when the buffers used to prepare the concentrates were substituted for the concentrates themselves, and a comparable concentration of sodium citrate was also found to be inhibitory. Coagulation factor VIII partially purified by gel filtration was not found to have an appreciable effect on lymphocyte transformation in vitro.This publication has 15 references indexed in Scilit:
- Coagulation Abnormalities following Intensive Plasma Exchange on the Cell SeparatorBritish Journal of Haematology, 2008
- Acquired immune deficiency syndrome: Retroviruses linked with AIDSNature, 1984
- Immunologic abnormalities in patients with hemophilia AThe Journal of Pediatrics, 1983
- Immunological abnormalities in haemophilia: are they caused by American factor VIII concentrate?BMJ, 1983
- A clinician and a scientist look at acquired a validation of immunology's theoretical foundationImmunology Today, 1983
- T-Lymphocyte Subpopulations in Patients with Classic Hemophilia Treated with Cryoprecipitate and Lyophilized ConcentratesNew England Journal of Medicine, 1983
- Impaired Cell-Mediated Immunity in Patients with Classic HemophiliaNew England Journal of Medicine, 1983
- A Therapeutic Concentrate of Coagulation Factors II, IX and X from Citrated, Factor VIII‐Depleted PlasmaVox Sanguinis, 1973
- Methods for the Production of Clinically Effective Intermediate and High-Purity Factor-VIII ConcentratesBritish Journal of Haematology, 1971